| abstract |
The invention provides compounds of the general formula (I):n n or a physiologically acceptable salt, solvate (e.g. hydrate) or a metabolically labile ester thereof in which nR¹ represents a hydrogen atom or a group selected from C₁₋₆alkyl or C₂₋₆alkenyl; nR² represents a hydrogen atom or a group selected from C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, C₃₋₆alkenyl, fluoroC₁₋₆alkyl, fluoroC₃₋₆alkenyl, phenyl, -(CH₂) k COR⁵ or -(CH₂) k SO₂R⁵; nR³ represents a hydrogen atom or a group selected from C₁₋₆alkyl optionally substituted by a hydroxy or C₁₋₆alkoxy group, C₂₋₆alkenyl, fluoroC₁₋₆alkyl, -(CH₂) m R⁶, -(CH₂) n COR⁷ or -(CH₂) p NR⁸COR⁹; nR⁴ represents a group selected from -CO₂H, -NHSO₂CF₃ or a C-linked tetrazolyl group; nR⁵ represents a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy or the group -NR¹⁰R¹¹; nR⁶ represents a phenoxy or benzyloxy group; nR⁷ represents a hydrogen atom or a group selected from hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, phenyl, phenoxy or the group -NR¹⁰R¹¹; nR⁸ represents a hydrogen atom or a C₁₋₆alkyl group; nR⁹ represents a hydrogen atom or a group selected from C₁₋₆alkyl, C₁₋₆alkoxy, phenyl, benzyl, phenoxy or the group -NR¹⁰R¹¹; nR¹⁰ and R¹¹ which may be the same or different each independently represent a hydrogen atom or a C₁₋₄alkyl group or -NR¹⁰R¹¹ forms a saturated heterocyclic ring which has 5 or 6 ring members and may optionally contain in the ring one oxygen atom; nk represents zero or an integer from 1 to 4; nm represents an integer from 1 to 4; nn represents zero or an integer from 1 to 4; and np represents an integer from 1 to 4. n The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders. |